Replimune is a clinical-stage biotechnology company pioneering oncolytic immunotherapies. Its lead candidate, RP1, is a proprietary herpes simplex virus engineered to infect and destroy tumor cells while triggering a systemic anti-cancer immune response. Used primarily in advanced solid tumors and melanoma, this approach aims to benefit patients with limited treatment options, potentially enhancing outcomes when combined with checkpoint inhibitors.
Get alerts when this topic surges in newsletters. Free to start.
Sign up freeExplore more trends:Trending Topics ·AI Trends ·Business Trends ·Finance Trends ·Technology Trends